AliveCor and PulseAI announced on Monday that PulseAI's AI heart-rhythm analysis will come to the Kardia App for KardiaCare subscribers in the first half of 2027, Tech Times reports. There is no price and no firm launch date yet.
Your watch decides your results
Apple Watch is slated to get four rhythm determinations (sinus rhythm, AFib, bradycardia, tachycardia) plus labels for premature ventricular contractions (PVCs). Samsung Galaxy Watch, Fitbit Sense and Withings ScanWatch would get sinus rhythm and AFib analysis only.
Why PVC labels matter
A PVC is an early extra heartbeat. Because smartwatch AFib checks look for irregular timing, PVCs can trigger false alerts. Tech Times cites a 734-patient study in which patients with PVCs were about three times more likely to get a false-positive AFib result from the Apple Watch ECG app. PulseAI's approach classifies each beat rather than judging overall regularity.
Read the fine print
- The FDA clearance letter limits use to adults when prescribed or under a physician's care.
- The partnership release does not say whether a prescription is needed for KardiaCare subscribers.
- The headline claim, inconclusive readings falling from 17.6% to 1.4%, comes from a hospital study of 296 participants on Apple Watch recordings, with PulseAI's founder among the authors and the company as a funder.
The takeaway for wearable owners: this is promising for cutting false alarms, but it is not yet a product you can buy. If you have palpitations or a known heart condition, a clinician, not a subscription, remains the right first call. Source: Tech Times.




